학술논문
Secukinumab in multi-failure psoriatic patients: the last hope?
Document Type
Academic Journal
Author
Magnano M; a Department of Specialized , Diagnostic and Experimental Medicine University of Bologna , Italy.; Loi C; a Department of Specialized , Diagnostic and Experimental Medicine University of Bologna , Italy.; Patrizi A; a Department of Specialized , Diagnostic and Experimental Medicine University of Bologna , Italy.; Sgubbi P; a Department of Specialized , Diagnostic and Experimental Medicine University of Bologna , Italy.; Balestri R; b Dermatology Division, Multizonale Santa Chiara Hospital , Trento , Italy.; Rech G; b Dermatology Division, Multizonale Santa Chiara Hospital , Trento , Italy.; Tasin L; b Dermatology Division, Multizonale Santa Chiara Hospital , Trento , Italy.; Girardelli CR; b Dermatology Division, Multizonale Santa Chiara Hospital , Trento , Italy.; Conti A; c Dermatology Unit, United Hospital of Ancona Polytechnic Marche University , Ancona , Italy.; Odorici G; c Dermatology Unit, United Hospital of Ancona Polytechnic Marche University , Ancona , Italy.; Campanati A; d Psoriasis Outpatient Clinic of the Polyclinic University Hospital , Modena , Italy.; Offidani AM; d Psoriasis Outpatient Clinic of the Polyclinic University Hospital , Modena , Italy.; Bardazzi F; a Department of Specialized , Diagnostic and Experimental Medicine University of Bologna , Italy.
Source
Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE
Subject
Language
English
Abstract
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also these agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a human monoclonal antibody that selectively neutralizes interleukin-17 A and is recently approved for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.